Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fe… Read more
Cumberland Pharmaceuticals Inc (CPIX) - Total Assets
Latest total assets as of September 2025: $65.90 Million USD
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) holds total assets worth $65.90 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cumberland Pharmaceuticals Inc - Total Assets Trend (2005–2024)
This chart illustrates how Cumberland Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cumberland Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cumberland Pharmaceuticals Inc's total assets of $65.90 Million consist of 48.2% current assets and 51.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.8% |
| Accounts Receivable | $11.70 Million | 15.5% |
| Inventory | $4.00 Million | 5.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $17.97 Million | 23.8% |
| Goodwill | $914.00K | 1.2% |
Asset Composition Trend (2005–2024)
This chart illustrates how Cumberland Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cumberland Pharmaceuticals Inc's current assets represent 48.2% of total assets in 2024, a decrease from 84.5% in 2005.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2024, down from 54.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 23.8% of total assets.
Cumberland Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Cumberland Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Cumberland Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Cumberland Pharmaceuticals Inc generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cumberland Pharmaceuticals Inc is currently not profitable relative to its asset base.
Cumberland Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 1.13 | 1.95 |
| Quick Ratio | 1.11 | 0.99 | 1.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.63 Million | $ 4.15 Million | $ 24.30 Million |
Cumberland Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Cumberland Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.24 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | $75.58 Million |
| Market Capitalization | $26.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cumberland Pharmaceuticals Inc's assets below their book value (0.35 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cumberland Pharmaceuticals Inc's assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cumberland Pharmaceuticals Inc (2005–2024)
The table below shows the annual total assets of Cumberland Pharmaceuticals Inc from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $75.58 Million | -7.57% |
| 2023-12-31 | $81.78 Million | -12.00% |
| 2022-12-31 | $92.93 Million | +10.02% |
| 2021-12-31 | $84.46 Million | -12.44% |
| 2020-12-31 | $96.46 Million | -7.73% |
| 2019-12-31 | $104.55 Million | -7.23% |
| 2018-12-31 | $112.69 Million | +20.87% |
| 2017-12-31 | $93.23 Million | -0.18% |
| 2016-12-31 | $93.40 Million | +1.62% |
| 2015-12-31 | $91.92 Million | -3.65% |
| 2014-12-31 | $95.41 Million | +8.89% |
| 2013-12-31 | $87.61 Million | -11.14% |
| 2012-12-31 | $98.59 Million | +3.22% |
| 2011-12-31 | $95.52 Million | +3.76% |
| 2010-12-31 | $92.05 Million | -11.25% |
| 2009-12-31 | $103.72 Million | +233.31% |
| 2008-12-31 | $31.12 Million | +7.61% |
| 2007-12-31 | $28.92 Million | +9.20% |
| 2006-12-31 | $26.48 Million | +160.30% |
| 2005-12-31 | $10.17 Million | -- |